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Platelet-activating factor (PAF) 1 is a mediator of inflammation and endotoxic
shock identified as 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (1-3) . PAF is
produced by appropriately stimulated basophils (4), monocytes/macrophages (5, 6),
polymorphonuclear neutrophils (6, 7), platelets (8), and endothelial cells (9, 10) .
A variety of stimuli induce these cells to synthesize PAR For example, basophils
produce PAF when sensitized by IgE (4), PMN, and macrophages upon phagocy-
tosis (5, 6), and endothelial cellswhen incubated with thrombin (9, 10), angiotensin,
or vasopressin (9) .
Evidence has accumulated (see reference 11 for review) that endotoxin-induced
inflammation is primarily mediated by IL-1 and TNF. We have recently shown that
TNF stimulates rat peritoneal macrophages (RPM), human polymorphonuclear neu-
trophils (PMN), and vascular endothelial cells to synthesize and release PAF (12) .
This activity ofTNF is regulated by cell-specific mechanisms, since PAF is rapidly
but transiently synthesized by macrophages (12), whereas PAF synthesis peaks 4-6
h after addition ofTNF in endothelial cells (12, 13) . Production of PAF by these
cells is stimulated alsoby IL-1 (14), with peak synthesis at 8-12 h (13) . In endothelial
cells, bothTNF and IL-1 induce an acetyltransferase activity required forPAF syn-
thesis (13, 14).
PAF shows a wide range of biological effects (see reference 15 for review): it in-
duces aggregation of platelets (4), promotes chemotaxis of neutrophils and mono-
cytes (16-18), increases vascular permeability, and alters the vascular tone (19) . These
activities of PAF show many similarities with some of the biological responses de-
scribed for TNF (20) . This observation led to the hypothesis that PAF may be an
important secondary mediator of the inflammation induced by TNF (12) .
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In previous experiments, we noticed that the serine proteinase inhibitor L-1-
tosylamide-2-phenylethylchloromethyl ketone (TPCK) drastically reduces PAF pro-
duction induced by TNF in RPM (12) and endothelial cells (13). These cells are
stimulated to synthesize and release measurable amounts of PAF only during incu-
bations in serum-free medium, due to the presence of a serum acetylhydrolase that
cleaves the 2-acetyl group from PAF (21). Therefore, it is not known from such ex-
periments whether plasma proteinase inhibitors may interfere with PAF production
similarly to TPCK. In the present investigation, we examined the effect of human
plasma fractions on TNRinduced PAF synthesis and release. Preliminary experi-
ments were carried out on PMN incubated with acid-treated serum to inactivate
PAF acetylhydrolase (21), but PAF production and release was nevertheless drasti-
cally inhibited. This finding led us to analyze different plasma fractions for the pres-
ence of inhibitors of PAF synthesis, which were subsequently identified as proteinase
inhibitors (antiproteinases).
Materials and Methods
Materials.
￿
Human and murine rTNF (hTNF and mTNF) were respectively gifts of Dr.
Tatsuro Nishihara of the Suntory Institute for Biomedical Research, Osaka, Japan, and of
Dr. Walter Fiers, University of Ghent, Ghent, Belgium. Human rIL-la was a gift of Im-
munex Corp. (Seattle, WA). Human plasma a,-proteinase inhibitor (PI) and a,-anti-
chymotrypsin (AC), rabbit anti-PI IgG, leukocyte myeloperoxidase, human neutrophil elastase
and cathepsin G, and human erythrocyte catalase were purchased from Athens Research
and Technology Inc. (Athens, GA). The chloromethyl ketones proteinase inhibitors MeO-
Suc-Ala2-Pro-ValCH2Cl and Z-Gly-Leu-Phe-CH2C1 were from Enzyme Systems, Inc. (Liver-
more, CA). Baker's yeast spores (BYS) were prepared by boiling baker's yeast for 30 min
in isotonic saline. Spores were collected by 10-min centrifugation at 1,500g and washed twice
with saline. To prepare opsonized spores (BYS-C3b), 20 mg of spores were incubated 30 min
at 37'C with 1 ml of fresh human serum, centrifuged and washed twice with Tris-buffered
Tyrode's solution (TT) without calcium and magnesium, pH 6.5, supplemented with 0.25%
delipidated BSA (TTBSA). [3H]PAF was synthesized by reacting 10 mM 1-octadecyl-2-lyso-
sn-3-phosphocholine (Bachem Feinkemikalien, Bubendorf, Switzerland) in methanol with
0.1 Ci of [3H]acetic anhydride (6 Ci/mmol; Amersham Int., Amersham, UK) in the pres-
ence of 32 .7 mM dimethylaminopyrimidine (22). The specific activity of [3H]PAF was 90
mci/mol.
Plasma Fractionation.
￿
Human plasma freshly collected in 5 mM EDTA was fractionated
on a 1 x 100 cm Sephacryl-200 superfine column (Pharmacia Fine Chemicals, Piscataway,
NJ), equilibrated with 0.01 M phosphate buffer, pH 7.4, and eluted with this buffer at VC
through a recording spectrophotometer (LKB Instruments, Inc., Gaithersburg, MD). Eluted
fractions were immediately assayed for PAF acetylhydrolase activity, pooled, frozen at -80OC,
and lyophilized. These fractions were reconsituted with distilled water before incubation with
PMN or RPM . A corresponding volume of elution buffer was used as control.
PAF Acetyllydrolase Assay.
￿
The PAF acetylhydrolase activity was measured according to
Blank et al. (22). Briefly, 0.5 ml of Sephacryl-200 column fractions were incubated for 10
min at 37 0C with 4 gM [3H]PAF (0.5 nCi) in polypropylene tubes. The reactions were
stopped by adding 0.5 ml of 1017o NaHC03 and 1 ml of chloroform, shaking, and separating
the organic phase by centrifugation. The upper water phase was extracted three times with
1-ml aliquots of chloroform, and the [3H]acetate in the water phase was measured by scin-
tillation counting.
Cell Preparation and Treatment.
￿
Human PMN were prepared as described (9) . Briefly, blood
from healthy donors was drawn into plastic tubes containing 5 mM EDTA and centrifuged
for 20 min at 700,x. Plasma and bully coat were removed, and pelleted cells were resuspended
in 2 volumes of 2 .5% gelatin (Difco Laboratories, Inc., Detroit, MI) in saline. The bulk of
the erythrocytes was removed by low speed centrifugation, and the remaining cells were pelletedby centrifugation for 20 min at 700 g. These cells were subjected to osmotic shock to elimi-
nate contaminating erythrocytes and were washed twice with TTBSA without calcium and
magnesium. Smears of cells stained with May-Gruenwald-Giemsa showed 85-95% PMN.
The cells were resuspended at 5 x 106/ml in TTBSA with calcium and magnesium, and
incubated at 37°C with the additions indicated in the text. Rat peritoneal macrophages and
human vascular endothelial cells were prepared and cultured as described (12).
Assay ofCell-associated andReleased PAF.
￿
In standard assays, 2.5 x 106 PMN or 106 RPM
were incubated in 0.5 ml reactions with TNF, 20 pl of BYS-C3b suspension (ti10 spores/cell)
or other additions indicated in the text. Endothelial cells were grown in multiwell plates (N5
x 105 cells/35-mm well) and treated in 1 ml of Iscove's medium containing 0.25% BSA.
Preincubation with proteinase inhibitors was for 20 min at 22°C . PAF released into the medium
and cell associated was isolated, characterized, and measured as described (12).
Results
Inhibition ofPAFSynthesis by Plasma Fractions.
￿
In preliminary experiments, human
PMN were prepared by different procedures and stimulated to produce PAF in in-
cubations with THE Only PMN prepared by differential centrifugation in buffer
containing 2.5% gelatin and used within 2 h responded reproducibly to TNF (data
not shown). These experiments were carried out in serum-free medium (12) because
of the presence of an enzymatic activity in serum that rapidly hydrolyses PAF (21,
22). This PAF acetylhydrolase can be inactivated by treating serum with 0.1 N HCl
at pH 3 (22). However, when serum treated in this way was added to incubations
of PMN and hTNF, an almost complete suppression of PAF production was still
observed (data not shown). This finding suggested that other inhibitors ofPAF syn-
thesis are present in serum.
To identify these inhibitors, huma plasma was fractionated by gel filtration chro-
matography (Fig. 1). The fractions eluted were tested on PMN in a standard assay
for hTNFmediated induction of PAF production . Two peaks of inhibitory activity
were clearly separated; PAF acetylhydrolase was detected only in the first peak (frac-
tions 1-3). Addition of these fractions presumablyresulted in hydrolysis of PAF released
by PMN in response to hTNE The second peak of inhibitory activity (fractions 7-9)
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FIGURE 1.
￿
Fractionation of human plas-
ma by chromatography on Sephacryl-200
and assay for inhibitors of TNFinduced
PAF synthesis. The plasma fractionation
and otherassays aredescribed in Materials
and Methods. The histogram shows the
percent inhibitionofPAF release by 50 ul
of plasma fractions preincubated for 30
min at 22°C with 2.5 x 106 PMN before
stimulation with 10 ng hTNF for 10 min
at 37°C. The PAFacetylhydrolase activity
ofplasmafractions (") isexpressed as cpm
of [3Hlacetate recovered in the inorganic
phase. The percent inhibitionofPAF syn-
thesis in assays carried out in the presence
ofanti-PI IgG is also indicated (A). These
cells were preincubated for 20 min at 22°C
with 0.1 mg of IgG before addition of 10
nghTNE Theelution volume ofbluedex-
tran (BD) and ofother marker proteins is
indicated by the arrows.1296
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was eluted afterBSA (Fig. 1). Inprevious experiments, the protease inhibitorTPCK
blockedthe synthesis ofPAF induced byTNF in RPM(12) and vascular endothelial
cells (13). Thus, it seemed possible that plasma proteinase inhibitors could have a
similar effect. Furthermore, the second peak ofinhibitory activity coeluted with PI
(Fig. 1). To identify this inhibitory activity with PI, we added anti-PI-neutralizing
IgG to column fractions, which were incubated with PMN before stimulation with
hTNE The inhibition ofPAF releasewasgreatly reducedwhen fraction 8 was treated
in this way, whereas, anti-PI IgG had less effect on the activity of fraction 9. The
identificationofthe inhibitorin fraction 8 as PI wasfurtherconfirmed by generating
oxidants with myeloperoxidase (Table I). Biologicaloxidants inactivate PI(23) and,
accordingly, suppressed the inhibitory activity offraction 8 to alargeextent in assays
with both PMN and RPM stimulated by hTNF and mTNF, respectively. The same
effect wasobserved when purified PIwas used in controlexperiments (Table 1). These
findings show that PI inhibits PAF release induced by TNF and raise the possibility
that other plasma antiproteinases may have a similar activity.
SynthesisofPAFcan be induced in PMN and RPM byphagocytosis ofopsonized
yeast spores (24). Thus, it was of interest to examine whether fraction 8 or PI in-
hibited PAF production stimulated by phagocytosis of BYS-C3b. Partial inhibition
ofPAF release (Table 1) and of cell-associated PAF synthesis (data not shown) was
observed in assays with both fraction 8 and PI. However, this inhibitory activity
was greatly increased when catalase, which decomposes hydrogen peroxides, was
added to the assays (Table I). Presumably, during phagocytosis, PMN and RPM
release peroxides that inactivate PI.
Inhibition of PAF Synthesis by Plasma Proteinase Inhibitors.
￿
The dose response to PI
inhibition was measured in standard TNF induction assays of PAF production by
neutrophils and macrophages. Completeinhibition ofPAFreleasewas observedwith
20 ltg/ml ofPI, and significant inhibition with 0.2 [tg/ml (Fig. 2 A). The dose re-
sponse to PI inhibition was similar for RPM (Fig. 2 B) and for cell-associated PAF
TABLE I
Effect of Oxidants on the Inhibition of PAF Production
For each experiment, 2 .5 x 106 PMN or 106 RPM were assayed in triplicate for PAF release induced by
10 ng/ml hTNF or mTNF, respectively, and by BYS-C3b (see Materials and Methods). The cells were prein-
cubated 30 min with plasma fraction $8 (described in Fig. 1) or 10 mg PI t 0 .03 U/ml of myeloperoxidase
and 0.05 U/ml of glucose oxidase, before addition of TNF. Alternatively, the cells were preincubated 20
min t 1,500 U of catalase and then stimulated with 10 jil of BYS-C3b suspension. The medium was har-
vested after 10 and 60 min from PMN and RPM, respectively. The mean ng of PAF released in the medi-
um t SD are indicated. When treated with TNF alone, the PMN and RPM released 6.8 t 0.7 and 9.1 t 1 .1
ng ofPAF, respectively. When treated with BYS-C3b alone, the PMN released 11 .6 t 2.1 ng of PAF and
the RPM 8.9 t 3 .2 ng. These values were taken as 100% to calculate the percent PAY released relative
to these controls.
Additions
Neutrophils
Plasma no. 8 PI
Macrophages
Plasma no. 8 PI
TNF 0.4 t 0.7 (6) 0.9 t 0.8 (13) 0 .4 t 0.7 (4) 0.3 t 0.5 (3)
TNF + myeloperoxidase 3.8 t 1 .1 (56) 7.9 t 0.6 (116) 6 .0 t 0 .7 (66) 6.8 t 1 .8 (75)
BYS-C3b 4.9 t 0.5 (42) 6.3 f 1 .5 (54) 1 .8 t 0.7 (20) 3.1 ± 1 .0 (35)
BYS-C3b + catalase 0.9 t 0.7 (8) 1 .7 t 1 .8 (15) ND 0.2 t 0.3 (2)CAMUSSI ET AL.
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FIGURE 2.
￿
Dose response ofthe inhibition of PAF release by
PI (") and AC (A) in neutrophils (A) andmacrophages (B).
Theamountsof PI or AC indicatedin theabscissa were added
to incubations containing either 2.5 x 106 PMNor 106RPM
for 30 min at 22°C before addition of 10 ng hTNF or mTNF,
respectively. ThePMNwere then incubated for10 minat 37°C,
whereas the RPMwere incubatedfor30 minbefore removing
the medium to measure PAF release.
in both cell types(data not shown). Since the experiments with humanplasma frac-
tions (Fig. 1) suggested that other proteins could be inhibitory for TNF induction
ofPAF synthesis, we assayed the human plasma proteinase inhibitor AC in parallel
experiments. This antiproteinase was slightly less effective than PI in decreasing
PAF release by PMN or RPM (Fig. 2). Essentially identical datawere obtained for
cell-associated PAF (data not shown).
Pretreatment with plasma proteinase inhibitors before TNF addition did not re-
sult in inhibition ofPAF synthesis. When PMN were preincubated for 30 min with
20 Ag/ml ofeither PI or AC and then washed, the amount ofPAF released 10 min
after addition of20 ng/ml hTNF was comparable with that released from control
cells preincubated without antiproteinases (data not shown). This finding suggests
that these proteins do not interact with a proteinase present in untreated PMN,
but presumably inhibit an enzyme released by these cells or activated on their sur-
faceafterhTNFaddition. This hypothesis may explain thelack ofeffect oftheprein-
cubation with PI, since this antiproteinase reacts slowly with zymogens by forming
stable complexes (see reference 25 for review).
Thesefindings showthat twodifferentplasma proteinase inhibitors interfere with
the induction ofPAF synthesis by THE It was therefore ofinterest to compare the
effect ofthese antiproteinases on PAF production induced by other stimuli, such
as phagocytosis ofBYS-C3b ortreatment withthe calcium ionophore A23187 (Table
II). Both PI and AC drasticallyinhibited PAF production induced byTNF, but had
no effect on cells treated with A23187. PI was somewhat inhibitory for PMN, but
clearly inhibitory for RPM incubated with BYS-C3b. The interpretation of these
data has to take into account the finding that oxidants produced during phagocy-
tosis of BYS-C3b inactivate PI, as shown by the experiment where the addition of
catalase increased the inhibitory activity ofPI (Table I). AC had no effect on PAF
production by PMN, whereas, it significantly inhibited PAF production by RPM
(Table II). At this time, we cannot distinguish between a lack of effect of AC on1298
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TABLE II
Effect of Proteinase Inhibitors on PAF Synthesis and Release
Neutrophils
￿
Macrophages
For each assay, 2.5 x 106 PMN or 106 RPM were preincubated for 30 min with 20 ug/ml of proteinase
inhibitors or kept as untreated controls. The cells were then treated for 10 min with 20 ng/ml hTNFor mTNF,
respectively, for 20 min with 20 wl of BYS-C3b suspension, or for 30 min with 1 Pg/ml of A23187 . PAF
released into the culture medium or cell associated was measured as described in Materials and Methods.
Each experiment was carried out in quadruplicate and the data shown are mean ng of PAF ± SD.
PMN stimulated by phagocytosis, or an inactivation ofthis antiproteinase during
the incubation ofPMNwith BYS-C3b. However, the effect ofAC on RPM suggests
that these cells differ from PMN in their sensitivity to different plasma proteinase
inhibitors.
In subsequent experiments, we examined whetherPI andAC inhibit the produc-
tion of PAF induced by hTNF in human vascular endothelial cells. The response
ofthese cells to hTNF is much slower than that ofRPM to mYNF (12, 13). There-
fore, PAF production was measured after 6 h ofincubation with hTNF (Table III).
Both PI andAC inhibited the productionofcell-associated PAF and its release, but
PI was more inhibitory than AC. This result indicates that plasma antiproteinases
TABLE III
The Effect of Serum Proteinase Inhibitors on the Stimulation of
PAF Production by hTNF in Human Vascular Endothelial Cells
For each assay, 2.5 x 105 cells were pretreated for 30 min with the proteinase
inhibitor indicated and then incubated for 6 h with 17 ng/ml hTNF. The cell-
associated and released PAF were measured as described in Materials and
Methods.
Treatment Released Cell associated Released Cell associated
None
TNF
TNF + PI
TNF + AC
0.4
7.6
1 .3
0.9
± 0.6
t 3.6
t 0.6
t 0.9
0.4 ± 0.8
8.3 t 3.2
0.5 t 0.5
2.5 t 4.2
0.8 ± 1 .2
12.4 ± 2 .6
0.5 ± 0.8
2.6 ± 1 .1
1 .7 ± 1 .2
12.1 ± 2 .9
0.9 ± 0.9
3.2 ± 1 .5
BYS-C3b 11.2 2.7 12 .1 ±3.0 15.4±2.2 16.2±3.2
BYS-C3b+PI 8.1 ±2.9 8 .9±3.0 3.3± 1 .6 7.4± 1 .2
BYS-C3b + AC 13.5 t 0.7 11.5 t 0.6 4.9 ± 1 .5 8.7 ± 2.4
A23187 11.3 ± 2.5 12 .0 t 2.0 22.5 ± 2.2 25.0 ± 3.0
A23187 + PI 14.5 ± 0.7 12 .0 ± 3.5 20.3 ± 1 .5 23.9 ± 4.4
A23187 + AC 14.3 ± 0.6 11 .5 t 0.6 22.0 ± 2.0 24 .3 ± 4.5
Additions gg/ml
PAF
Cell associated
ng
Released
None - 0.6 ± 0.2 0
hTNF - 6.1 ± 2.0 3.1 ± 0.6
hTNF+PI 5 3.8± 1 .1 0.8±0.2
hTNF + PI 10 1 .6 ± 0.4 0.7 1 0.3
hTNF+AC 5 4.7 ± 1 .3 1 .8±0.5
hTNF+AC 10 2 .3±0.7 1 .1 ±0.7CAMUSSI ET AL.
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inhibit PAF production by vascular endothelial cells that were previously shown to
respond to hTNF in serum-free medium (12, 13).
Production of PAF can be induced in PMN and vascular endothelial cells also
by treatment with IL-1, a cytokine that shares several activities with TNF (25). It
was thus of interest to establish whether the plasma proteinase inhibitors interfere
with the release of PAF or with the production of cell-associated PAF induced by
IL-1. Both PI and AC significantly inhibited the production of PAF in PMN and
endothelial cellstreated with IL-1 (Table IV). This finding suggests that antiproteinases
interfere with some common step in the induction of PAF synthesis stimulated by
TNF and IL-1.
Effect ofProteinases on PAF Synthesis.
￿
The inhibition of PAF production by PI and
AC may be explained by the inhibitionof specific proteinase(s) in TNFtreated cells.
To show that a proteinase can trigger PAF synthesis, PMN and RPM were treated
with human neutrophil elastase. This proteinase induced PAF production and re-
lease in both cell types (Fig. 3). The time course of PAF production and the dose
response to different concentrations of elastase were determined for both PMN and
RPM. The maximum level ofcell-associated PAF was observed in PMN after 2 min
(the first time point sampled), whereas, PAF release peaked 5 min after the addition
of elastase (Fig. 3 A). Both cell-associated and released PAF subsequently decreased
to undetectable levels after 60 min. PMN were stimulated to produce PAF by elastase
concentrations as low as 10 ng/ml, but significant PAF release was observed with
greater elastase concentrations (2 ug/ml; Fig. 3 B). The RPM were stimulated to
produce maximal amounts ofPAF 10 min after addition ofelastase (Fig. 3 C). About
equal amounts of cell-associated and released PAF were detected at this time; similar
PAF levels were present at 30 min, but the cell-associated PAF decreased to unde-
tectable levels afterwards (Fig. 3 C). Greater amounts of elastase were required to
induce PAF production and release in RPM than in PMN (Fig. 3 D).
Vascular endothelial cells were similarly stimulated to produce PAF by the addi-
tion of elastase (Fig. 4). Maximum levels of cell-associated and released PAF were
present after 30 min; the amount of PAF decreased afterwards, and it returned to
TABLE IV
The Effect of Serum Proteinase Inhibitors on Synthesis of PAF by Neutrophils
and Vascular Endothelial Cells Stimulated with IL-1
For each assay, 2.5 x 106 PMN or 2 .5 x 105 endothelial cells were preincubated 30 min at
22°C in 0.5 ml of medium containing 10 kg/ml of proteinase inhibitors; the cells were then
incubated for 30 min (PMN) or 6 h (endothelial cells) with 0.1 nM IL-1 . The PAF released
in the medium or cell associated was measured as described in Materials and Methods.
Cells Additions Released
PAF
Cell associated
ng
IL-1 4.0 t 0.1 4.9 t 0.9
Neutrophils IL-1 + PI 1 .5 t 0.7 1 .8 t 0.8
IL-1 + AC 2.5 t0.3 2.9t 1 .1
IL-1 1.7 t 0.2 4.6 t 0.7
Endothelial IL-1 + PI 0.5 t 0.4 1 .1 t 0.8
IL-1 + AC 0.8 t 0.1 3.3-0.61300
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a basal level after 3 h (Fig. 4A) . Therefore, the addition of elastase stimulated PAF
production much faster than either TNF or IL-1 (13). Endothelial cells were op-
timally stimulated by 1 wg/ml of elastase, but higher concentrations of this enzyme
were somewhat inhibitory (Fig. 4B). The amount ofcell-associated PAF was greater
than that of PAF released into the medium with all the elastase concentrations tested,
but N387o of the PAF produced was released from endothelial cells treated with 0.1
or 1 gg/ml of this protease (Fig. 4 B). These findings show that proteinases secreted
by neutrophils and macrophages can directly stimulate these cells and vascular en-
dothelial cells to produce PAR
Another neutrophil proteinase, cathepsin G, was effective in inducing PMN to
synthesize PAF (Fig. 5). Both cell-associated and released PAF peaked 10 min after
addition of cathepsin G and decreased to basal levels after 60 min (Fig. 5 A). Rela-
tively low cathepsin G concentrations were effective in inducing synthesis of PAR
but somewhat greater concentrations were required to obtain significant PAF re-
lease (Fig. 5 B). In subsequent experiments, 2 jig/ml of chymotrypsin induced the
release of 5.3 t 0.1 ng of PAF from PMN in 30 min. This finding suggests that
proteinases with relatively broad substrate specificity can induce PAF production.
Elastase and cathepsin G have a variety of biological effects independent oftheir
proteolytic activity. To test whether these enzymes can trigger PAF release after in-
FIGURE 3.
￿
The effect of elastase on production
ofcell-associated PAF (") and release ofPAF (41)
in neutrophils (A and B) or macrophages (C and
D). Standard assays were incubated for the time
indicated with 1 gg/ml of elastase (A and C) or
for 10 min with the concentration of elastase in-
dicated in the abscissa (B and D).
FIGURE 4.
￿
The effect ofelastase on the pro-
duction ofcell-associated PAF (A) and on the
release of PAF (0) by vascular endothelial
cells. Standard assays were incubated for the
time indicated with 1 pg/ml ofelastase (A) or
for 30 min with the concentration of elastase
indicated inthe abscissa (B). The data shown
represent the average of six experiments.4
a
a
2
B
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FIGURE 5.
￿
The effect of cathepsin G on the
synthesis of cell-associated (A) and released
PAF(0)by PMN. 2.5 x 106 PMNwere in-
cubated for the time indicated with 1 Wg/ml
ofcathepsin G(A) or for 10 minwith the con-
centration ofcathepsin Gindicated in the ab-
scissa. Experiments were carried out in tripli-
cate, and the average ng PAF are shown.
activation of such activity, elastase and cathepsin G were treated at pH 6.5 either
with 1 mM DFP or with 0.05 mM PMSF. When 4 gg/ml of these inactivated en-
zymes were added to PMN as described in Figs. 4 and 5, no release of PAF was
detected after 10 or 30 min (data not shown). Therefore, we can exclude that an-
tiproteinasesinhibit PAF synthesis by interfering with bindingofelastase or cathepsin
G to critical target sites.
Effect of Chloromethyl Ketone Proteinase Inhibitors on PAF Synthesis and Release.
￿
Our
workinghypothesis is that aproteinase is activated on theplasma membrane of sus-
ceptible cells or released into the medium after TNF binds to its receptor. The ex-
periments described above could not identify a specific proteinase involved in trig-
gering PAF synthesis, since elastase and cathepsin G were almost equally effective.
Another approach to identify a unique proteinase is based on the effect of specific
inhibitors, such as MeO-Suc-Ala2-ProValCH2Cl andZ-Gly-Leu-PheCH2Cl that in-
hibit elastase and cathepsin G, respectively (26). TNF-induced PAF synthesis was
measured in PMN treated with low concentrations (10 ELM) of these proteinase in-
hibitors. The cathepsin G inhibitor was more effective than the elastase inhibitor
in decreasing PAF synthesis and release (Table V). A similar result was obtained
TABLE V
Effect of Chloromethyl Ketone Proteinase Inhibitors on Synthesis of Cell-associated and
Released PAF by Neutrophils
For each assay, 2.5 x 106 PMN were preincubated for 30 minat 22°C with 10 gM proteinase
inhibitors, or with 0.1 mM inhibitorswhen these compounds were removed andthe cells washed
twice with fresh medium before induction of PAF synthesis. Thecells were incubated 10 min
at 37°C with 1 nM hTNF or for 20 minwith 20 wl ofBYS-C3b suspension. Each experiment
was carried out in triplicate and the data shown are mean ng of PAF t SD.
Treatment Cell associated Released
hTNF 8.0 t 0 .4 5.5 t 0.3
hTNF + MeO-Suc-Ala2-Pro-Va1CH2C1 6.5 t 1 .9 6.1 t 2.3
hTNF + Z-Gly-Leu-PheCH2Cl 3 .9 t 1 .3 1 .0 t 0.5
hTNF + Z-Gly-Leu-PheCH2Cl (washed) 3 .1 t 0.1 1 .2 t 0.6
BYS-C3b 8.1 t 3 .5 8.5 t 2.3
BYS-C3b + Me0-Suc-Ala2-Pro-Va1CH2Cl 7 .3 t 3 .1 7.4 t 2.1
BYS-C3b + Z-Gly-Leu-PheCH2Cl 2 .6 t 1 .5 2.2 t 1 .1
BYS-C3b + Z-Gly-Leu-PheCH2Cl (washed) 1 .2 t 0.7 2.7 t 1 .71302
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with PMN stimulated to synthesize PAF by phagocytosis of BYS-Mb (Table V).
Addition ofgreater concentrations ofthe elastase inhibitor, up to 0.1 mM, did not
result in further decrease of PAF synthesis (data not shown).
The inhibition of PAF production by the cathepsin Ginhibitor was irreversible,
as expected for a peptide containing a chloromethyl ketone group that binds cova-
lently to serine proteinases. This was shown by adding 0.1 mM inhibitor to PMN
for30min; after washingthesecells, production ofPAF stimulated byhTNF orphago-
cytosis ofyeast spores was still markedly inhibited (Table V). The hTNFmediated
production ofcell-associated PAF decreased also by 81° Jo in endothelial cells treated
with 0.1 mM cathepsinGinhibitor, whereas, itonlydecreased by 32o 7o incellstreated
with 0.1 mM elastase inhibitor (data not shown). These results suggest that a pro-
teinase that is preferentially inactivated by the cathepsin Ginhibitor is involved in
promoting PAF synthesis induced either by TNF or by phagocytosis. However, this
suggestion should be considered with some caution, since we do not know whether
these inhibitors diffusewithdifferent kinetics into PMN and vascularendothelialcells.
Similar results were obtained withless specific serine proteinase inhibitors. PMN
were treated either with 1 mM DFP or with 50 uM PMSF for 10 min in TTBSA,
pH 6.5. The PMN were washed twice and then incubated with hTNF or with BYS-
C3b, as described in Table I. PAF release was inhibited 96% and 90%, respectively,
in PMN treated with DFP or PMSF and stimulated with hTNF. PAF release was
inhibited 87% and 91%, respectively, in PMN treatedwithDFP orPMSF andstimu-
lated by phagocytosis of CYS-Mb.
Discussion
The plasma proteinase inhibitors PI and AC impair synthesis and release ofPAF
induced byTNF and IL-1. PI and AC inhibit PAF synthesis at concentrations N100-
and ti10-fold lower thanthose present in serum(N2 mg/ml and -0.45 mg/ml, respec-
tively; see reference 25 for references). Therefore, it is unlikely that PMN, macro-
phages, or endothelial cells can synthesize and release significant amounts ofPAF
when exposed to the vast excess of antiproteinases present in serum. Synthesis of
PAF may requiretheinactivation oftheseproteinase inhibitors, or it may be limited
to zones of close contact between cells where antiproteinases are excluded. PI can
be inactivated by oxidation oftwo methionyl residues in the reactive site (25). Such
inactivation is observed in rheumatoid synovial fluid, where PI containing methio-
nine sulfoxide residues isrecovered (25). Therefore, this oxidized antiproteinase would
not inhibit PAF synthesisby PMN or macrophages participating in the rheumatoid
inflammatory response. However, no comparable mechanism to inactivate AC is
known and there are several other antiproteinases in serum that might inhibit PAF
synthesis, but have not yet been examined.
The hypothesis that PAF synthesis mayoccur in zones ofclose cell contact is sup-
ported by recent observationsonthe fibrinogenolysiscatalyzed by neutrophil elastase
(26). This enzyme is active inthe presence ofphysiological concentrations ofitsmost
effective inhibitor, PI (25), as shown by the appearance ofa specific fibrinopeptide
in plasma (26). The fibrinogenolysic activity offree elastase is inhibited by low con-
centrations of serum, whereas, the activity of PMN migrating across fibrinogen-
coated filtersis incompletely blocked, even in the presence ofundiluted serum (26).
Weitz et al. (26) suggest that the access of antiproteinases is prevented in zones ofCAMUSSI ET AL.
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close contact between PMN and fibrinogen as an explanation for the presence of
circulating fibrinopeptide.
In viewofthese findings, itseemspossiblethat PAF isonly synthesized and released
in zones ofthe cell plasma membrane that adhere to other cells or to extracellular
matrix. Appropriate stimuli, such as TNF or IL-1, may induce competent cells to
produce PAF by interacting with specific receptors over the whole cell surface, but
synthesis andrelease ofPAFmayberestricted to zonesthatexcludeantiproteinases.
According to this hypothesis, PAF production may be localized and its effects may
belimited to target cells in close contact with producer cells. Furthermore, the pres-
ence in serum ofthe acetylhydrolase that rapidly degrades PAF supports the notion
that PAF acts in a localized way.
The antiproteinases have no effect on PAF synthesis stimulated by the calcium
ionophore A23187, which mayinvolve activation ofproteinkinase C (27). This sug-
gests that antiproteinases do not directly inhibit the biosynthesis ofPAF, but inter-
fere with some step in a pathway leading to PAF synthesis. We propose that after
TNF or IL-1 bind to their receptors, a proteinase becomes activated at the cell sur-
face or is released in the medium. This hypothesis is based on the observation that
PMNpreincubated with plasma antiproteinases andthen washed respond normally
to hTNF However, PMN preincubated with the chloromethyl ketone proteinase in-
hibitors andthen washed do not respond tohTNF (Table V). These inhibitors react
with zymogens and may diffuse into cells, whereas, plasma antiproteinases react
slowly with zymogens (25) and cannot diffuse into cells.
The hypothesis that proteinases are involved in the induction of PAF synthesis
by TNF or IL-1 led us to assay their effect on PMN, RPM, and endothelial cells.
Neutrophil elastase and cathepsin Gstimulated PAF synthesis to levels comparable
with those observed after addition of TNF or phagocytosis. It seems possible that
these enzymes cleave some protein on the cell surface and that PAF is synthesized
subsequently to this proteolysis. Furthermore, proteinase-treated PMN, RPM, and
endothelial cells synthesizePAF faster than cells treated withTNF, sincePAFproduc-
tion peaks in PMN N10 min after TNF addition (our unpublished observations),
in RPM at 30 min (12), and in endothelial cells at 4-6 h (13). This finding suggests
that proteinases can shortcut the pathway that leads from the binding of TNF or
IL-1 to their receptors to synthesis of PAF.
Thepresent experimentshave not identified a specific proteinase that may be ac-
tivated in TNFtreated cells. PI is inhibitory for PAF synthesis at lower concentra-
tions than AC, the antiproteinase that shows the fastest time of association with
cathepsin G (25). However, the chloromethyl ketone inhibitor specific for this en-
zyme decreases PAF synthesis more effectively than the corresponding elastase in-
hibitor (Table V). Therefore, these experiments are inconclusive, andthe hypothet-
icalproteinase activated in cells treated with TNFor IL-1 has not yet been identified.
Synthesis ofPAF induced by proteinases may playa significant role in the inflam-
matory responseofendothelial cells to activatedPMN andmacrophages. These cells
release elastase, which induces synthesis and release ofPAR This factor inturn may
promote chemotaxis ofPMN and monocytes(16-18) and increases vascular perme-
ability (19) by autocrine or paracrine mechanisms. Furthermore, both PI and AC
inhibit PAF synthesis stimulated by phagocytosis in RPM (Table II). Similarly, a
cathepsinGinhibitordecreasesphagocytosis-stimulatedPAF synthesisinPMN (Table1304
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V). These findings suggest that PAF production induced by TNF and IL-1 shares
some common step(s) with the stimulation of PAF synthesisby phagocytosis. Thus,
it seems possible that antiproteasesmayinterferewith a general mechanism forPAF
synthesis in response to a variety of physiological stimuli. Such a mechanism pre-
sumably requires proteinase(s) activity.
The synthesis of PAF requires phospholipase A2-like activity (28). It has been
proposed that the peripheral membrane proteins lipocortins block phospholipase
A2 activity by sequestering phosolipid substrates rather than by a direct interaction
with this enzyme (29). Cirino et al. (30) recently reported that perfusion of isolated
guinea pig lungswith recombinanthuman lipocortin I inhibits the release ofthrom-
boxane that is formed by the lipoxygenase pathway from arachidonic acid. There-
fore, lipocortins applied extracellularly can inhibit phospholipase A2-like activity.
An hypothesis consistent with ourfindings is that proteolytic cleavage oflipocortins
or related proteins on the cell surface may promote activation of phospholipase A2.
Alternative explanations for the role of proteinases cannot be excluded at this time.
For example, these enzymes may inactivate an inhibitor of lyso-PAF acetyltrans-
ferase. Experiments directed at testing these hypotheses are currently in progress.
It is relevant to point out that the present findings provide evidence for a link
in a chain of regulatory mechanisms that may control the production of mediators
of inflammation. TNF induces fibroblasts and other cells to secrete IFN-a2 (31).
This cytokine is identical to hepatocyte-stimulating factor and induces synthesis of
all major acute phase proteins, including plasma antiproteinases, in human hepa-
toma cellsand ratprimaryhepatocytes (32). Therefore, TNF stimulates production
of mediators of inflammation such as PAF, but at the same time, via IFN-R2/hepa-
tocyte-stimulating factor, induces synthesis of antiproteinases that inhibit produc-
tion of this mediator.
Summary
TNF and IL-1 stimulate the synthesis and release of platelet-activatingfactor (PAF)
by neutrophils and vascular endothelial cells. Serum inhibits PAF production even
afterinactivation ofan acetylhydrolasethat degrades PAR Human plasma was frac-
tionated by gel filtration chromatography, and two inhibitory fractions were detected,
one containing PAFacetylhydrolase activity and the other ai-proteinase inhibitor.
Low concentrations of this antiproteinase and of human plasma al-antichymotryp-
sin inhibited TNFinduced PAF synthesis in neutrophils, macrophages, and vascular
endothelial cells. Both antiproteinases also inhibited PAF production stimulated by
phagocytosis in macrophages and induced with IL-1 in neutrophils or with TNF
in vascular endothelial cells. These results suggestthat aproteinase activated on the
plasma membrane or secreted by these cells is involved in promotingPAFsynthesis.
Indeed, addition of elastase to macrophages, neutrophils, andendothelial cells stimu-
lated synthesisand release ofPAF much faster than THE A similar stimulation was
observed in incubations with cathepsin G. To identify a proteinase activatedin TNF-
treated cells, neutrophils andendothelial cellswere incubatedwith specific chloromethyl
ketone inhibitors of elastase and cathepsin G. SynthesisofPAF was significantly in-
hibited by low concentrations of the cathepsin G inhibitor. The finding that an-
tiproteinases are inhibitory at concentrations 100-fold lower than those present in
plasma raises questions as to the ability of TNF and IL-1 to stimulate neutrophilsCAMUSSI ET AL.
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in circulation or endothelial cells to synthesize PAR We propose that PAF produc-
tion is limited to zones ofclose contact between cells, which exclude antiproteinases.
Receivedfor publication 19 May 1988 and in revisedform 6 July 1988.
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